Eiger BioPharmaceuticals Analyst Ratings
Eiger BioPharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/29/2023 | 248.88% | Citigroup | $4 → $3 | Maintains | Buy |
| 06/30/2023 | 481.46% | Baird | $3 → $5 | Maintains | Outperform |
| 09/07/2022 | 5482.04% | BTIG | $57 → $48 | Maintains | Buy |
| 08/09/2021 | 3039.9% | Citigroup | $26 → $27 | Maintains | Buy |
| 04/03/2020 | 3737.66% | Wedbush | $35 → $33 | Maintains | Outperform |
| 01/22/2020 | 3505.07% | Ladenburg Thalmann | $28 → $31 | Maintains | Buy |
| 06/26/2019 | 2458.44% | Citigroup | → $22 | Initiates Coverage On | → Buy |
| 01/29/2019 | 5365.75% | Baird | → $47 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月29日 | 248.88% | 花旗集团 | $4→$3 | 维护 | 买 |
| 2023/06/30 | 481.46% | 贝尔德 | $3→$5 | 维护 | 跑赢大盘 |
| 09/07/2022 | 5482.04% | BTIG | $57→$48 | 维护 | 买 |
| 08/09/2021 | 3039.9% | 花旗集团 | $26→$27 | 维护 | 买 |
| 04/03/2020 | 3737.66% | 韦德布什 | $35→$33 | 维护 | 跑赢大盘 |
| 2020/01/22 | 3505.07% | 拉登堡·塔尔曼 | $28→$31 | 维护 | 买 |
| 2019年06月26日 | 2458.44% | 花旗集团 | →$22 | 开始承保 | →购买 |
| 2019年01月29日 | 5365.75% | 贝尔德 | →$47 | 开始承保 | →跑赢大盘 |
What is the target price for Eiger BioPharmaceuticals (EIGR)?
艾格生物制药(EIGR)的目标价是多少？
The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by Citigroup on August 29, 2023. The analyst firm set a price target for $3.00 expecting EIGR to rise to within 12 months (a possible 248.88% upside). 3 analyst firms have reported ratings in the last year.
花旗集团于2023年8月29日报道了艾格生物制药(纳斯达克：EIGR)的最新目标价。这家分析公司将目标价定为3美元，预计Eigr将在12个月内升至(可能上涨248.88)。3家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Eiger BioPharmaceuticals (EIGR)?
艾格生物制药(EIGR)的最新分析师评级是多少？
The latest analyst rating for Eiger BioPharmaceuticals (NASDAQ: EIGR) was provided by Citigroup, and Eiger BioPharmaceuticals maintained their buy rating.
分析师对艾格生物制药(纳斯达克代码：EIGR)的最新评级由花旗集团提供，艾格生物制药维持买入评级。
When is the next analyst rating going to be posted or updated for Eiger BioPharmaceuticals (EIGR)?
艾格生物制药(EIGR)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eiger BioPharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eiger BioPharmaceuticals was filed on August 29, 2023 so you should expect the next rating to be made available sometime around August 29, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公开财务报表，与艾格生物制药的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。艾格生物制药的上一次评级是在2023年8月29日提交的，所以你应该预计下一次评级将在2024年8月29日左右的某个时候公布。
Is the Analyst Rating Eiger BioPharmaceuticals (EIGR) correct?
分析师对艾格生物制药(EIGR)的评级正确吗？
While ratings are subjective and will change, the latest Eiger BioPharmaceuticals (EIGR) rating was a maintained with a price target of $4.00 to $3.00. The current price Eiger BioPharmaceuticals (EIGR) is trading at is $0.86, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的艾格生物制药(EIGR)评级维持不变，目标价在4.00美元至3.00美元之间。艾格生物制药(Eigr)目前的交易价格为0.86美元，超出了分析师的预测区间。